

Peer Review File

Article Information: <https://dx.doi.org/10.21037/acr-22-41>

ROUND 1

Reviewer A

Here are a few remarks:

1- Concerning the case history, could you specify the month and year of diagnosis?

The initial presentation was in June 2021.

Changes in the text: This has been added to case history (Page 3, line 12).

2- Could you describe the radiological abnormalities at the end of the "case history" paragraph at the outset; this would help identify the key elements from the start ?

Changes in the text: Initial MRI has been placed after case history paragraph (Page 4, line 1).

3- Concerning sarcoidosis:

Can you specify the year of diagnosis? *Year of diagnosis Jan 2021.*

Was there any associated mediastinal lymph node involvement? *Yes*

Did the patient receive corticosteroids before or during methotrexate and what dose and duration?

Yes the patient received oral prednisone prior to methotrexate at 20mg daily for 5 months.

What dose and duration of methotrexate did he receive? *He was on methotrexate 20mg weekly for the past 3 months.*

Changes in the text: Information has been added to background paragraph (Page 4, line 11).

4- Concerning imaging:

Could had red arrows to show the lesions?

Changes in the text: Red arrows added (Figure 1, Figure 2)

5- Concerning histologic report, could you replace the "+" by "," ?

Changes in the text: We have modified as advised (Page 7, line 5)

6- Concerning the case, do you know if a 18-FDG PET and a serum EBV PCR have been performed?

This patient did not have a 18-FDG PET.

In November 2021, he had an EBNA antibody test which was 'reactive'.

Changes in the text: Above information added to text (Page 8, line 6)

7- Concerning radiotherapy, could you specify the field of irradiation ?

The field of irradiation was the cervical spine.

Changes in the text: Information added to text (Page 8, line 2)

8- Concerning the discussion:

What do you think about liquid biopsy which could avoid some surgeries in primary CNS lymphoma?

Cirillo M, Craig AFM, Borchmann S, Kurtz D. Liquid biopsy in lymphoma: molecular methods and clinical applications. *Cancer Treat.*

Rev. 91, 102106 (2020).

Liquid biopsy is a developing technique that has the potential to reduce the need for open biopsy in selected cases. However, more research and data is required on the utility of this technique before it can be employed in routine practice.

Changes in the text: Added paragraph on liquid biopsy (Page 12, line 4)

Reviewer B

This case-based article is a fine example of a summary on a disease (In this case PCNSL), and the challenges with getting the right diagnosis and start relevant treatment. Especially the discussion section can be used to look up good points and thoughts if a doctor sees a similar case in own clinic.

This article does not bring any new knowledge, but the case is well written and good illustrations are included.

Therefore, I recommend accept.

ROUND 2

Review comments: All recommendations have been respected.